| LDR | | 00000nam u2200205 4500 |
| 001 | | 000000432468 |
| 005 | | 20200224131051 |
| 008 | | 200131s2019 ||||||||||||||||| ||eng d |
| 020 | |
▼a 9781085733519 |
| 035 | |
▼a (MiAaPQ)AAI13902268 |
| 040 | |
▼a MiAaPQ
▼c MiAaPQ
▼d 247004 |
| 082 | 0 |
▼a 610 |
| 100 | 1 |
▼a Glumac, Paige M. |
| 245 | 10 |
▼a Targeting CD133 in Androgen Receptor Indifferent, Neuroendocrine Differentiated Aggressive Variant Prostate Cancer. |
| 260 | |
▼a [S.l.]:
▼b University of Minnesota.,
▼c 2019. |
| 260 | 1 |
▼a Ann Arbor:
▼b ProQuest Dissertations & Theses,
▼c 2019. |
| 300 | |
▼a 137 p. |
| 500 | |
▼a Source: Dissertations Abstracts International, Volume: 81-03, Section: B. |
| 500 | |
▼a Advisor: LeBeau, Aaron. |
| 502 | 1 |
▼a Thesis (Ph.D.)--University of Minnesota, 2019. |
| 506 | |
▼a This item must not be sold to any third party vendors. |
| 520 | |
▼a An increasing number of men are developing a lethal, non-androgen receptor (AR) driven form of prostate cancer (PCa) known as aggressive variant prostate cancer (AVPC). Therapeutic options for AVPC are limited, and the development of novel therapeutics is significantly hindered by the inability to accurately monitor the disease through imaging. This underscores the critical need to develop improved imaging agents for AVPC. Targeted imaging agents, such as those developed for prostate-specific membrane antigen (PSMA) have made significant progress in imaging metastatic prostate adenocarcinoma |
| 590 | |
▼a School code: 0130. |
| 650 | 4 |
▼a Pharmacology. |
| 650 | 4 |
▼a Medicine. |
| 690 | |
▼a 0419 |
| 690 | |
▼a 0564 |
| 710 | 20 |
▼a University of Minnesota.
▼b Pharmacology. |
| 773 | 0 |
▼t Dissertations Abstracts International
▼g 81-03B. |
| 773 | |
▼t Dissertation Abstract International |
| 790 | |
▼a 0130 |
| 791 | |
▼a Ph.D. |
| 792 | |
▼a 2019 |
| 793 | |
▼a English |
| 856 | 40 |
▼u http://www.riss.kr/pdu/ddodLink.do?id=T15492352
▼n KERIS
▼z 이 자료의 원문은 한국교육학술정보원에서 제공합니다. |
| 980 | |
▼a 202002
▼f 2020 |
| 990 | |
▼a ***1008102 |
| 991 | |
▼a E-BOOK |